Arthritis Care Res:RA早期手骨密度下降可预测侵蚀风险增高

2014-07-31 周泳 丁香园

尽管改变病情抗风湿药(DMARDs)的联用使类风湿性关节炎(RA)得到了更好的控制,但仍有一些患者出现进展性侵蚀性病变。早期治疗对患者预后有着积极的意义,研究表明,在“窗口”期对RA进行早期强化治疗可获得良好结局,能减少患者侵蚀性病变及继发残疾的发生。此外,在极早期(前12周)进行RA治疗是12个月时无侵蚀性进展的最好预测指标。对有进展性关节损伤风险的患者做到早期诊断,可让他们提前接受包括生物制剂

尽管改变病情抗风湿药(DMARDs)的联用使类风湿性关节炎(RA)得到了更好的控制,但仍有一些患者出现进展性侵蚀性病变。早期治疗对患者预后有着积极的意义,研究表明,在“窗口”期对RA进行早期强化治疗可获得良好结局,能减少患者侵蚀性病变及继发残疾的发生。此外,在极早期(前12周)进行RA治疗是12个月时无侵蚀性进展的最好预测指标。对有进展性关节损伤风险的患者做到早期诊断,可让他们提前接受包括生物制剂在内的强化治疗。

RA早期的疾病活动性指标并不能作为12个月时侵蚀损害的预测因子,因此需要在关节损害发生前的疾病早期发掘其他有预测价值的指标。在关节侵蚀出现前,RA最早的影像学改变是关节周围的骨质减少。既往研究表明,RA早期骨密度(BMD)降低与后续的关节损伤相关;尽管在研究中应用数字化x线片测量法(在数字化射线照片的基础上使用专业软件计算掌骨BMD)对BMD进行测量十分有效,但其临床应用尚未成熟。

此项研究使用双能x线吸收法(DXA)测量手BMD,探讨RA确诊后的头6个月内BMD降低能否作为侵蚀改变的早期预测指标。研究由澳大利亚阿德雷德皇家医院Black RJ等进行,结果于2014年4月在《关节炎护理与研究》(Arthritis Care Res (Hoboken))杂志上发布。

研究共纳入106名接受目标治疗的患者,均为早期RA患者,无DMARD治疗史。采用双能x线吸收法测量基线时间和6个月时的手BMD,分别在基线时间和12个月时行手、足射线检查,并使用Sharp/van der Heijde修正评分表进行评分。使用K-均值聚类算法将患者分为两组:根据患者从基线时间到6个月时BMD的绝对变化值,分为BMD降低组和骨密度无降低组。采用多元回归分析(障碍模型)对两组侵蚀性病变发生的风险及其侵蚀分数进行分析。

结果显示,6个月时手BMD降低与12个月时的侵蚀分数相关(P = 0.021)。多元回归分析显示,手BMD降低(P = 0.046)以及发病年龄大(≥50岁,P = 0.014)与侵蚀性病变的发生相关,此外,基线时间的侵蚀评分及抗环瓜氨酸肽水平均与侵蚀严重程度/进程相关。

接受目标治疗的RA患者中,早期手BMD降低提示12个月时侵蚀病变发生的风险更高,这为预防侵袭病变损害的强化治疗提供了研究基础。

原始出处:

Black RJ1, Spargo L, Schultz C, Chatterton B, Cleland L, Lester S, Hill CL, Proudman SM.Decline in hand bone mineral density indicates increased risk of erosive change in early rheumatoid arthritis.Arthritis Care Res (Hoboken). 2014 Apr;66(4):515-22. doi: 10.1002/acr.22199.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1972335, encodeId=036319e23353c, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Sep 27 13:32:00 CST 2014, time=2014-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355898, encodeId=d59213558980f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561562, encodeId=6bab1561562af, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567571, encodeId=0720156e57168, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1972335, encodeId=036319e23353c, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Sep 27 13:32:00 CST 2014, time=2014-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355898, encodeId=d59213558980f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561562, encodeId=6bab1561562af, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567571, encodeId=0720156e57168, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]
    2014-08-02 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1972335, encodeId=036319e23353c, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Sep 27 13:32:00 CST 2014, time=2014-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355898, encodeId=d59213558980f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561562, encodeId=6bab1561562af, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567571, encodeId=0720156e57168, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]
    2014-08-02 liuxiaona
  4. [GetPortalCommentsPageByObjectIdResponse(id=1972335, encodeId=036319e23353c, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Sep 27 13:32:00 CST 2014, time=2014-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355898, encodeId=d59213558980f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561562, encodeId=6bab1561562af, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567571, encodeId=0720156e57168, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Aug 02 00:32:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]
    2014-08-02 liuxiaona

相关资讯

ACR 2013:女性长期喝碳酸饮料或患增类风湿性关节炎风险

  圣迭戈——护士健康研究(NHS)与NHSⅡ汇总分析的结果显示,每天喝甜的碳酸饮料的女性罹患血清阳性类风湿性关节炎的风险大大增加。  在NHS的190万人-年和NHSⅡ的150万人-年的随访中,分别发生了563例确诊新发血清阳性类风湿性关节炎和320例血清阳性类风湿性关节炎。这两项研究共招募了238,131名定期填写饮食频率问卷的美国女性注册护士。  布里格姆妇女医院的Yang Hu医生在美国风

NEJM:托法替尼对类风湿性关节炎显示持久的安全性

一项综合的安全性分析显示,托法替尼用于类风湿关节炎(RA)的严重不良事件随着时间的推移仍保持稳定,发生率并未在长期用药患者中出现升高。例如,在接受托法替尼(Tofacitinib )治疗长达6个月的患者中,严重感染发生率(最常见严重不良事件)为2.57/100病人年,在口服这款Janus激酶抑制剂Tofacitinib 超过42个月的患者中,严重感染发生率为1.89/100病人年。最近有关Tofa

类风湿性关节炎八类用药

类风湿性关节炎是一种异质性疾病,所有人群均有可能会患上此病,它会引发口腔溃疡、关节脱位、库欣综合征等疾病,类风湿性关节炎的种类很多,表面上表现虽相似,但有不同类型,因而病情轻重、发展、预后、结局都可有所不同,尽管临床上区分这些类型还有困难,但从概念上说,是否所有类风湿性关节炎都一样治疗,就很值得商榷了。 据数据显示,研究人员对532例类风湿性关节炎患者追踪的结果表明,其中症状出现少于6个月者

AAOS 2014:RA不增加同期双侧TKA围手术期并发症发生

严重的类风湿性关节炎(RA)可以引起成人残疾,造成行动和功能障碍。而且相对于骨性关节炎(OA)患者,RA患者双侧膝关节屈曲挛缩、多平面多关节畸形以及较差的健康状况都会给外科医生增加手术难度。我们比较同期双侧膝关节置换术(BTKA)的RA和OA患者的30天死亡率、住院并发症率和发病率、死亡率的风险。 方法:分析该医院1998~2011年间行BTKA的240例RA患者和3680例OA患者资料。统计患

NEJM:生物制剂与常规治疗急性类风湿性关节炎的效果相似

很少有盲法试验对使用缓解疾病的抗风湿性药物常规治疗与生物制剂治疗经甲氨喋呤治疗仍存在活动性疾病的类风湿性关节炎患者的疗效进行比较,而上述病情在类风湿性关节炎治疗中较为常见。James R. O'Dell博士等人对此进行了深入研究,他们发现,对于经甲氨喋呤治疗仍存在活动性疾病的类风湿性关节炎患者的临床获益而言,三种缓解疾病的抗风湿性药物(甲氨喋呤、柳氮磺吡啶、以及羟氯喹)联合治疗或依那西普加甲氨喋呤

辉瑞Xelganz获多国批准用于类风湿性关节炎(RA)

辉瑞(Pfizer)今日宣布,Xelganz(tofacitinib citrate)获多个国家批准,用于对现有疗法反应不足的类风湿性关节炎(RA)患者的治疗。其中,瑞士是欧洲首个获批准入的国家,瑞士医药管理局(Swissmedic)批准以5mg和10mg剂量Xelganz每日2次(BID)作为单药或与一种疾病修饰非生物抗风湿剂(DMARD,包